Drugs / tasimelteon
tasimelteon
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed circadian rhythm sleep disorder, jet lag type 3 milestones | |||||
| Rejected (CRL) | US (FDA) | HETLIOZ | circadian rhythm sleep disorder, jet lag type | 2026-01-08 | “the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form.” vandapharma.com ↗ |
| Rejected (CRL) | US (FDA) | HETLIOZ | circadian rhythm sleep disorder, jet lag type | 2019-08-16 | “received a complete response letter (CRL) on August 16, 2019 from the FDA related to the supplemental New Drug Application (sNDA) of HETLIOZ ®” vandapharma.com ↗ “records relating to the FDA's denial of Vanda's sNDA for HETLIOZ ® in jet lag disorder.” vandapharma.com ↗ |
| Filed | US (FDA) | HETLIOZ | circadian rhythm sleep disorder, jet lag type | 2018-12-20 | “FDA has accepted the filing of Vanda's Supplemental New Drug Application for HETLIOZ ® (tasimelteon) for the treatment of jet lag disorder.” vandapharma.com ↗ “Vanda submitted its sNDA in October 2018 for approval to market HETLIOZ ® to treat jet lag disorder.” vandapharma.com ↗ |
| Filed insomnia 2 milestones | |||||
| Filed | US (FDA) | HETLIOZ | insomnia | 2023-11-08 | “The sNDA for HETLIOZ ® in insomnia was accepted for filing by the FDA” vandapharma.com ↗ |
| Rejected (CRL) | US (FDA) | HETLIOZ | insomnia | — | “received a complete response letter (CRL) from the FDA related to the supplemental New Drug Application (sNDA) for HETLIOZ ® in the treatment of insomnia.” vandapharma.com ↗ |
| Filed non-24-hour sleep-wake syndrome 3 milestones | |||||
| Filed | EU (EMA) | HETLIOZ | non-24-hour sleep-wake syndrome | 2014-06-03 | “its Marketing Authorization Application (MAA) for oral HETLIOZ ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA)” vandapharma.com ↗ “In June 2014 , the EMA accepted for evaluation Vanda's Marketing Authorization Application for oral HETLIOZ ® capsules for the treatment of Non-24.” vandapharma.com ↗ |
| Filed | US (FDA) | HETLIOZ | non-24-hour sleep-wake syndrome | 2013-07-29 | “On July 29, 2013 Vanda announced that the U.S. Food and Drug Administration ( FDA ) accepted the filing and granted priority review classification to Vanda's New Drug...” vandapharma.com ↗ “has accepted the filing and granted a priority review classification to Vanda's New Drug Application (NDA) for tasimelteon” vandapharma.com ↗ |
| Filed | US (FDA) | — | non-24-hour sleep-wake syndrome | 2013-05-31 | “today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for tasimelteon” vandapharma.com ↗ |
| Filed Smith-Magenis syndrome 1 milestone | |||||
| Filed | EU (EMA) | HETLIOZ | Smith-Magenis syndrome | — | “Vanda submitted a Marketing Authorization Application for HETLIOZ ® and a Line Extension Application for HETLIOZ LQ ® to the European Medicines Agency” vandapharma.com ↗ “Vanda's MAA for HETLIOZ ® and HETLIOZ LQ ® for Smith-Magenis Syndrome (SMS) is pending with the EMA.” vandapharma.com ↗ “a Line Extension Application for HETLIOZ LQ ® to the European Medicines Agency” vandapharma.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansion | US (FDA) | HETLIOZ | — | 2020-12-01 | fda.gov ↗ |
| Approved | EU (EMA) | Hetlioz | — | 2015-07-03 | europa.eu ↗ |
| Approved | US (FDA) | HETLIOZ | — | 2014-01-31 | fda.gov ↗ |
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05922995 | Sep → Dec 2023 | REM sleep behavior disorder | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT06323655 | Jul → Aug 2018 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02776215 | Oct 2016 → Dec 2017 | Smith-Magenis syndrome, autism spectrum disorder, non-24-hour sleep-wake syndrome | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01637636 | Jun → Aug 2012 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01578057 | Apr → Jun 2012 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01526746 | Feb → Jun 2012 | impaired renal function disease | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01540500 | Feb → Mar 2012 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01477619 | Nov 2011 → Jan 2012 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01402076 | Aug 2011 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01271387 | Jan → Aug 2011 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03291041 | Jul 2016 → Nov 2017 | circadian rhythm sleep disorder, jet lag type | Vanda Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT00490945 | Jul 2004 → Mar 2005 | circadian rhythm sleep disorder | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02231008 | Sep 2015 → Nov 2018 | Smith-Magenis syndrome, circadian rhythm sleep disorder | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT01428661 | Sep 2011 → Jan 2013 | major depressive disorder | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 311 trials · 4 met primary | ||||||
| Phase 3 | NCT06953869 | Apr 2025 → Nov 2027 expected | insomnia | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06701396 | Oct 2024 → Jun 2025 overdue | circadian rhythm sleep disorder, delayed sleep phase type | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05361707 | Jul 2021 → Jul 2025 | autism spectrum disorder, sleep disorder | Vanda Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT04652882 | Dec 2020 → Sep 2026 | circadian rhythm sleep disorder | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03373201 | Oct 2017 → Mar 2018 | circadian rhythm sleep disorder, jet lag type | Vanda Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01429116 | Oct 2011 → Jan 2015 | non-24-hour sleep-wake syndrome | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01430754 | Sep 2011 → Dec 2012 | non-24-hour sleep-wake syndrome | Vanda Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01218789 | Oct 2010 → Dec 2024 | non-24-hour sleep-wake syndrome | Vanda Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT01163032 | Aug 2010 → Nov 2012 | non-24-hour sleep-wake syndrome | Vanda Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00548340 | Nov 2007 → Feb 2008 | insomnia | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00291187 | Feb → Aug 2006 | insomnia | Vanda Pharmaceuticals | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02130999 | May 2014 | non-24-hour sleep-wake syndrome | Vanda Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 33
| Date | Issuer | Release |
|---|---|---|
| 2026-09-29 | Vanda Pharmaceuticals | Results Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). |
| 2026-03-03 | Vanda Pharmaceuticals | Regulatory Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review the Center for Drug Evaluation and Research's (CDER) proposal to refuse approval of Vanda's supplemental new drug application (sNDA) for HETLIOZ ® (tasimelteon) in the treatment of jet lag disorder. |
| 2026-01-08 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder vandapharma.com ↗
the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form. |
| 2025-09-25 | Vanda Pharmaceuticals | Results Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" vandapharma.com ↗
Improvements in LPS persisted through the follow-up time points (Nights 22 and 29, p < 0.01). |
| 2025-08-18 | Vanda Pharmaceuticals | Regulatory In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder vandapharma.com ↗
In a sweeping win for Vanda, the Court set aside the FDA's action. |
| 2024-03-06 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia vandapharma.com ↗
Consistent with that notification, the FDA has issued a CRL, indicating that the FDA cannot approve the sNDA in its present form. |
| 2024-02-05 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia vandapharma.com ↗
No deficiencies were disclosed by the FDA in the notification, and the FDA stated that the notification does not reflect a final decision on the information under review. |
| 2022-09-07 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals Announces Notice of Opportunity for an FDA Hearing on the sNDA for HETLIOZ® In Jet Lag Disorder vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ ® (tasimelteon) to treat jet lag disorder. |
| 2020-12-01 | Vanda Pharmaceuticals | Regulatory FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ ® (tasimelteon) capsule and liquid formulations for the treatment of adults and children, respectively, with nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS). |
| 2020-08-03 | Vanda Pharmaceuticals | Regulatory FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda's applications for Smith-Magenis Syndrome (SMS). |
| 2019-08-19 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder vandapharma.com ↗
In the CRL, the FDA asserted that these measures demonstrating improved sleep are of unclear clinical significance. |
| 2019-07-22 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder vandapharma.com ↗
No deficiencies were disclosed by the FDA in this notification, and the FDA stated that this notification does not reflect a final decision on the information under review. |
| 2018-12-20 | Vanda Pharmaceuticals | Regulatory FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application for Review in the Treatment of Jet Lag Disorder vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the filing of Vanda's Supplemental New Drug Application for HETLIOZ ® (tasimelteon) for the treatment of jet lag disorder. |
| 2018-12-10 | Vanda Pharmaceuticals | Results Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that HETLIOZ ® (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome (SMS) in a pivotal placebo controlled clinical study. |
| 2018-09-12 | Vanda Pharmaceuticals | Results HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning Performance vandapharma.com ↗
Tasimelteon did not impair measures of driving performance, whereas the active control, zopiclone, showed significant impairment. |
| 2018-05-23 | Vanda Pharmaceuticals | Results HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel vandapharma.com ↗ |
| 2018-03-05 | Vanda Pharmaceuticals | Results HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ ® , a circadian regulator, demonstrated significant and clinically meaningful benefits in nighttime and daytime symptoms of jet lag disorder. |
| 2015-08-05 | Vanda Pharmaceuticals | Results HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet vandapharma.com ↗
In treated patients, daytime sleep decreased by 46 minutes per day in the worst 25% of days and nighttime sleep increased by 57 minutes per day during the worst 25% of nights. |
| 2015-07-07 | Vanda Pharmaceuticals | Regulatory HETLIOZ® Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the European Commission (EC) approved HETLIOZ ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union (EU). |
| 2015-07-02 | Vanda Pharmaceuticals | Regulatory Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a HETLIOZ® patent, number 9,060,995 ('995 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. |
| 2015-04-24 | Vanda Pharmaceuticals | Regulatory Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of HETLIOZ ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union (EU). |
| 2014-06-03 | Vanda Pharmaceuticals | Regulatory European Medicines Agency Accepts HETLIOZ™ (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). |
| 2014-01-31 | Vanda Pharmaceuticals | Regulatory FDA Approves HETLIOZ™ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder vandapharma.com ↗
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has approved HETLIOZ™ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). |
| 2013-11-14 | Vanda Pharmaceuticals | Regulatory FDA Advisory Committee Recommends Approval of HETLIOZ™ for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind vandapharma.com ↗
"We are extremely pleased that the FDA's advisory committee has recommended that the FDA approve HETLIOZ™ for the treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos M.D ., Vanda's President and Chief Executive Officer. |
| 2013-10-16 | Vanda Pharmaceuticals | Regulatory Vanda Pharmaceuticals Announces FDA Advisory Committee Meeting On November 14, 2013 vandapharma.com ↗
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has notified the company of the scheduling of a Peripheral and Central Nervous System Drugs Advisory Committee meeting on November 14, 2013 , for the review of Vanda's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ ™ , for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. |
| 2013-07-29 | Vanda Pharmaceuticals | Regulatory FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind vandapharma.com ↗
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the filing and granted a priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. |
| 2013-06-17 | Vanda Pharmaceuticals | Results Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder vandapharma.com ↗
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95 th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. |
| 2013-06-05 | Vanda Pharmaceuticals | Results Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder vandapharma.com ↗
Tasimelteon also demonstrated significant improvement versus placebo across a number of sleep and wake parameters including measures of total sleep time, nap duration, and timing of sleep, as well as in the Clinical Global Impression of Change (CGI-C), an overall global functioning scale. |
| 2013-05-31 | Vanda Pharmaceuticals | Regulatory Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind vandapharma.com ↗
Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for tasimelteon, a circadian regulator. |
| 2013-01-31 | Vanda Pharmaceuticals | Results Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint vandapharma.com ↗
The clinical study did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale (HAMD-17) after 8 weeks of treatment as compared to placebo. |
| 2012-12-18 | Vanda Pharmaceuticals | Results Vanda Announces Positive Phase III Results For Tasimelteon In The Treatment Of Non-24-Hour Disorder vandapharma.com ↗
Tasimelteon succeeded in the primary endpoint of Entrainment of the melatonin (aMT6s) rhythm as compared to placebo. |
| 2012-10-15 | Vanda Pharmaceuticals | Results Tasimelteon Restores Daily Cortisol Rhythms in Blind Patients with Non-24-Hour Disorder vandapharma.com ↗
Vanda Pharmaceuticals (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, reported today that tasimelteon has been shown for the first time to restore daily cortisol rhythms in totally blind patients suffering from Non-24-Hour Disorder (Non-24). |
| 2012-01-26 | Vanda Pharmaceuticals | Results Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder vandapharma.com ↗
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that tasimelteon was shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder). |
All press releases naming this drug 49 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tasimelteon | “Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.” PMID 19054552 ↗ Dec 200824“VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks” NCT00548340 ↗ |
| Known as | BMS-214,778 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103822 ↗ |
| Known as | HETLIOZ | “Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder” PMID 32754110 ↗ Jul 2020 |
| Known as | Hetlioz lq | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103822 ↗ |
| Known as | VEC-162 | “Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.” PMID 19054552 ↗ Dec 2008 |
| Action | Activate | “the melatonin agonist tasimelteon (VEC-162) for treatment of transient insomnia associated with shifted sleep and wake time.” PMID 19054552 ↗ Dec 2008 |
| Modality | Small molecule | — CHEMBL2103822 ↗ |
| Route | Oral | “20 mg taken orally 30 minutes prior to bedtime.” NCT00291187 ↗ |